Liquidia CorpLQDAEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Liquidia Corp is a late-stage biopharmaceutical firm focused on developing and commercializing innovative inhaled therapies for respiratory and rare diseases. It uses its proprietary PRINT particle engineering tech to create optimized drug products, with core markets in North America covering pulmonary arterial hypertension and asthma indications.
LQDA Q4 FY2025 Key Financial Metrics
Revenue
$92.0M
Gross Profit
N/A
Operating Profit
$19.8M
Net Profit
$14.6M
Gross Margin
N/A
Operating Margin
21.5%
Net Margin
15.8%
YoY Growth
3054.6%
EPS
$0.18
Liquidia Corp Q4 FY2025 Financial Summary
Liquidia Corp reported revenue of $92.0M (up 3054.6% YoY) for Q4 FY2025, with a net profit of $14.6M (up 137.9% YoY) (15.8% margin).
Key Financial Metrics
| Total Revenue | $92.0M |
|---|---|
| Net Profit | $14.6M |
| Gross Margin | N/A |
| Operating Margin | 21.5% |
| Report Period | Q4 FY2025 |
Liquidia Corp Quarterly Revenue & Net Profit History
Liquidia Corp results over the last 2 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $92.0M | +3054.6% | $14.6M | 15.8% |
| Q3 FY2025 | $54.3M | +1121.7% | $-3.5M | -6.5% |
Income Statement
| Q3 2025 | Q4 2025 | |
|---|---|---|
| Revenue | $54.3M | $92.0M |
| YoY Growth | 1121.7% | 3054.6% |
Balance Sheet
| Q3 2025 | Q4 2025 | |
|---|---|---|
| Assets | $276.0M | $327.9M |
| Liabilities | $253.9M | $283.2M |
| Equity | $22.1M | $44.7M |
Cash Flow
| Q3 2025 | Q4 2025 | |
|---|---|---|
| Operating CF | $-9.8M | $44.2M |